Introducing the Delaware Technology Park Incubator Space at the STAR Campus.
Delaware Technical Park Incubator Space | Tenants
ACT Solutions Corp
ACT Solutions Corp (Adaptive Cosmetic Technology Solutions) is an experienced team of scientists serving the cosmetic and topical pharmaceutical industries from laboratories in Delaware and Ohio. ACT Solutions Corp uses the technology power of Adaptive Aesthetic Design™, Advanced Emulsion Solutions™ , and Formulating for Efficacy™ including exciting FFE™ Software to speed development of products and ingredients with enhanced performance, aesthetics and consumer appeal.
The Adaptive team is led by 30- year industry veteran, Mark Chandler, and includes members experienced in the formulation of advanced skin treatment products, sunscreens, color cosmetics, mild cleansers and natural formulations.
The most frequent reason for obstructive sleep apnea is collapse of the upper airways. This leads to an undersupply of oxygen and, in turn, leads to a waking reaction in the body. This region in the throat and pharynx is trained and strengthened with Asate’s novel, scientifically demonstrated training process and device usage.
After studies were conducted in Europe from 2003 – 2014 with significant results in curing sleep apnea and snoring, Asate has developed seminars, self-training and online therapy coupled with a novel medical didgeridoo device to overcome sleep issues. Today, over 1,500 patients in Europe have utilized Asate technology to improve the quality of their lives. Asate, founded by Alex Suarex, established US headquarters in 2015 and is developing various offerings for the U.S. market.
DEact, LLC was founded on the belief that safe, environmentally friendly solutions can improve pharmaceutical disposal practices in both healthcare facilities and residential communities. DEact technology offers the ability to chemically denature a broad range of pharmaceutical substances at the molecular level so they can be safely stored on site, reducing environmental impact and decreasing the opportunity for diversion. DEact utilizes current hospital technology, targeting the most common areas where drugs are disposed of and wasted.
Justin Stas and Trevor Brown founded the company in 2016 after graduating from the University of South Carolina and writing their thesis on the Chemical Denaturing of Controlled Substances.
Coming to DTP@STAR in early 2017.
Coming to DTP@STAR in December 2016.
Napigen’s goal is to unleash and transform the power of cellular organelles into unique, high-value products for agriculture and industrial biotechnology. The company targets organelle genomes of chloroplasts and mitochondria with its novel technology and empowers the engineering of recalcitrant genomes for a wide range of organisms. Napigen’s products in agriculture will enable better pest and herbicide controls, better yield under normal and stressful conditions, and better production of high-yielding hybrid seeds. Technology will also be applied to create microbes with significantly high productivity of proteins and RNAs and complex biomolecules including nutraceutical and pharmaceutical compounds. In the future, Napigen technology will extend into human and animal healthcare to cure diseases caused by mitochondrial dysfunction.
Napigen was founded in 2016 by Hajime Sakai, Ph.D., CEO at Napigen, who has 18 years of experience in agricultural research and development at DuPont; Ganesh Kishore, Ph.D., former Chief Biotechnologist at Monsanto and former Chief Biotechnology Officer at DuPont, along with Roger Wyse, Ph.D., former a Dean at Rutgers and University of Wisconsin, Madison; Jay Keasling, Ph.D., CEO at the Joint BioEnergy Institute and The Hubbard Howe Jr. Distinguished Professor of Biochemical Engineering at UC Berkeley.
Unlike traditional compound medicines, antibodies are biomacromolecular medicines that enable high effectiveness and low toxicity therapies for various human diseases including cancer, infectious and autoimmune diseases and Alzheimer’s. OriMAbs Ltd. has developed cutting-edge technology utilizing a yeast display library for efficient discovery of fully human antibodies, which will greatly minimize side effects and improve the therapy window over current antibody medicines. OriMAbs Ltd. engages in discovery and development of novel human antibodies for cancer therapy and also provides customer service in antibody discovery and engineering. Yueheng Han and Aizhi Zhao founded OriMAbs in March 2015.
Plum Unified Communications
Plum Unified Communications supports companies of all sizes with collaboration utilizing Microsoft Office 365 and Skype for Business, enabling them to fully optimize deployment and leverage software capabilities. PlumUC conducts online and in-person immersive education sessions.
This past year has been very transformative for PlumUC founder, Greg Plum, who delivered a TEDx talk on cloud technology, published a book, “Getting Started with Skype for Business Online”, and educated over 1,000 students on optimizing communication services.
Prelude Therapeutics was founded with the mission of discovering new medicines for the treatment of cancer and rare diseases. Prelude’s approach is based on targeting emerging intervention points in chromatin regulation utilizing a collaborative environment among Prelude scientists, external contract research organizations and academic institutions. By leveraging the extensive pharmaceutical backgrounds of founding scientists, a nimble and high energy start up culture, a highly respected scientific advisory board and strong investor support, Prelude aspires to be a company dedicated to addressing life threatening diseases.
Kris Vaddi is the founder and CEO of Prelude Therapeutics and the founding scientist of Incyte in Delaware serving as a Group Vice President until recently. Kris initiated and championed JAK research at Incyte that led to the discovery, development and approval of Jakafi® (ruxolotinib) for Myelofibrosis and Polycythemia Vera. Kris received his Doctorate in Veterinary Medicine from APAU in India and his Ph.D. from University of Florida.
Juan Luengo is founding scientist and Vice President of Drug Discovery and Research Director at Prelude Therapeutics. Before joining Prelude, Juan worked for 27 years at GlaxoSmithKline, where he was Head of Chemistry in the Cancer Epigenetics Research Department, Oncology R&D. Juan holds a Ph.D. degree in Organic Chemistry from the University of Michigan and a B.S. in Chemistry from the Universidad Complutense of Madrid, Spain.
RAAD is a new, customizable core application that enables companies to identify, evaluate, score and address supply chain and enterprise risks that can impact organizational performance and profitability. RAAD is built in Java, using powerful connectors into ERP systems that pull together all of the unique permutations of potential risk to an organization right from a company’s own data. RAAD is an innovative and unique risk management offering that can become an organization’s unifying platform for enterprise risk management.
RAAD360’s leadership is made up of former SAP America Platinum Consultants, customization experts, business process management experts and former business executives, who bring decades of valuable business and IT experience. Software development operations span the globe, with development groups in China (Beijing), India (Hyderabad) and the United States.
Sepax Technologies, Inc.
Headquartered in Delaware USA, Sepax Technologies, Inc. is a privately held company founded in November 2002 that provides solutions to challenges in chromatographic separations. Sepax develops and manufactures HPLC consumables, bulk media and equipment for chemical and biological separations in liquid chromatography. Sepax has been developing a wide range of intellectual property in the areas of particle synthesis, surface modification, LC column packing, bulk media production and purification process development. Sepax Quality Management System is ISO 9001:2008 certified.
Dr. Xueying Huang is the President and founder of Sepax Technologies, Inc. He earned his Ph.D. degree in chemistry from University of Delaware conducted post-doctoral research at Stanford University.
SAS Nanotechnologies, LLC.
SAS Nanotechnologies, LLC (Smart Advanced Sustainable Nanotechnologies) is founded on the core idea that a better future can be achieved by innovation and development of smart, advanced and sustainable materials. The company specializes in synthesis, processing and applications of organic conducting nanomaterials including graphene, polyaniline, polypyrrole and PEDOT, which are lightweight, flexible and can conduct electricity and have applications in variety of areas ranging from electronics to energy storage to sensors. SAS Nanotechnologies is developing composite-based, organic, conducting materials and polymers that can prevent corrosion efficiently while repairing itself (smart, self-healing coating) under abrasion and extreme conditions.
Company founder Sumedh Surwade has invented and pioneered several nanotechnology related applications and graduated with a B. Tech degree from the Institute of Chemical Technology, Mumbai, India, M.S. degree from the University of Texas at Dallas and a Ph.D. from the University of Massachusetts.
Spin In® is an OEIP program whose purpose, through experiential learning, is to stimulate innovation and entrepreneurship within the undergraduate student communities by partnering the external entrepreneurial community with teams of interdisciplinary students charged with developing solutions to their real world business challenges.
Early stage entrepreneurial companies, who don’t have the resources or expertise to develop their promising, innovative ideas, form a partnership with OEIP. A team of undergraduate students is assembled, with the interdisciplinary skills (technical, marketing, business, design, policy, etc.) needed to address the challenge.
STF Technologies, LLC.
STF Technologies was formed in 2013 with core competencies in the development of custom, advanced, composite materials containing shear thickening fluids and the integration of these materials into protective products. STF engineers develop rate-sensitive materials for a wide variety of protective applications, ranging from materials designed to protect against low-speed, blunt impact to those used for high-velocity ballistic impacts. Partners include NASA, the U.S. Army, the National Science Foundation, and a number of corporate and small business customers. Technology applications include needle-resistant gloves, rate-sensitive impact protective materials for concussion mitigation, and advanced space suits that meet the protection, mobility, and durability requirements of future crewed missions.
The company was co-founded by Richard Dombrowski and Norman Wagner. Dr. Dombrowski earned a Ph.D. in Chemical Engineering from the University of Queensland and a B.Ch.E. from the University of Delaware. Professor Norman J. Wagner is the Robert L. Pigford Chaired Professor of Chemical Engineering at the University of Delaware. He has over 20 years of experience with STF science and technology, is a member of the National Academy of Engineering and was recognized with the Siple Award from the U.S. Army in 2002 for his co-invention of shear thickening fluid body armor.
The STAR building houses core labs for use by teams of clinical and academic researchers. These shared spaces encourage basic scientists, clinicians, physician scholars, and students to work together conducting interdisciplinary and translational research that changes people’s lives.
The STAR Campus is conveniently located along the I-95 corridor between New York and Washington, D.C. with easy access to the interstate.
Within Newark, the site is adjacent to the University of Delaware’s main campus and directly across the street from the UD Athletics Complex, which boasts a 23,000 seat stadium and the Bob Carpenter Center, which is now home to the 87ers, the NBA’s Development League team for the 76ers.
The development spans multiple phases, with Phase I highlighting the knowledge of the University of Delaware College of Health Sciences and Phase II integrating health care experts from across the region and nation. By bringing together academics and research with businesses all focused on health and life sciences, Delle Donne & Associates plans to create a synergy on the site that will benefit not only those on the Health Sciences Complex but the greater Newark community.
Transit on the STAR Campus is also expanding with not only University buses providing transportation to the main campus but also through the Newark Regional Transportation Center, which provides services via SEPTA and Amtrak. Plans are underway to relocate and improve the current train station and, eventually, the expand the service.
Interested in Becoming a Tenant?
COLLEGE OF HEALTH SCIENCES
The University of Delaware is an equal opportunity/affirmative action employer and Title IX institution. The University of Delaware complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. The University of Delaware does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. For a list of the University’s complete policies, please visit this page.